+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nuclear Radiation Therapeutic Drugs Market - Global Forecast 2026-2032- Product Image
Nuclear Radiation Therapeutic Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Nuclear Radiation Therapeutic Drugs Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6138929
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Nuclear Radiation Therapeutic Drugs Market is projected to reach USD 8.14 Billion in 2026. It is expected to continue growing at a CAGR of 15.75%, reaching USD 19.56 Billion by 2032.

Nuclear Radiation Therapeutic Drugs: Executive Overview

Nuclear radiation therapeutic drugs use radioactive isotopes linked to targeting molecules to deliver radiation to diseased tissue. Clinical adoption is shaped by evidence of benefit, isotope availability, manufacturing controls, specialist workforce capacity, regulatory requirements, and the ability to coordinate imaging, treatment, radiation safety, and follow-up care. The field includes established radiopharmaceutical approaches as well as emerging targeted therapies and combination regimens.

Theranostics and Supply Resilience Are Reshaping the Landscape

The landscape is shifting toward theranostic pathways that pair diagnostic imaging with a corresponding therapeutic isotope, enabling patient selection and response assessment. Progress is also being driven by advances in radioligand design, improved chelator chemistry, more precise dosimetry, and broader use of multidisciplinary treatment pathways. At the same time, short isotope half-lives make production scheduling, specialized transport, hot-cell capacity, and local or regional distribution especially important. Regulatory harmonization and investment in isotope production are therefore becoming central to reliable clinical access.

Artificial Intelligence Is Strengthening Selection, Planning, and Monitoring

Artificial intelligence can support nuclear radiation therapeutic drugs by helping interpret molecular imaging, identify eligible patients, segment lesions, estimate absorbed dose, and integrate clinical and laboratory data. Predictive models may also assist treatment scheduling, toxicity monitoring, and longitudinal response assessment. However, useful deployment requires representative datasets, transparent validation, human oversight, cybersecurity, and clear accountability for clinical decisions. AI should augment specialist judgment rather than replace radiopharmacists, nuclear medicine physicians, oncologists, medical physicists, or radiation-safety professionals.

Regional Insights: Uneven Infrastructure Defines Access

North America benefits from advanced nuclear medicine infrastructure, specialist expertise, and established clinical research networks, while access can vary by geography and reimbursement pathway. Europe has strong academic and regulatory capabilities, with implementation influenced by national health systems, cross-border logistics, and isotope policy. Asia-Pacific combines sophisticated centers in markets such as Japan, South Korea, and Australia with rapidly expanding capabilities elsewhere, creating varied access conditions. Latin America is developing through referral centers and international collaboration but faces constraints in isotope logistics, financing, and specialized staffing. The Middle East is investing in advanced healthcare and nuclear medicine capacity, with access concentrated in leading institutions. Africa remains highly heterogeneous, and progress depends on reliable isotope supply, workforce development, radiation-safety systems, and regional referral networks.

Group Insights: Cooperation and Regulation Shape Deployment

ASEAN countries are pursuing different levels of nuclear medicine development, making training, shared protocols, and coordinated logistics valuable for regional access. BRICS members combine substantial scientific and industrial capabilities with wide differences in healthcare infrastructure, domestic isotope production, and regulatory maturity. The European Union benefits from collaborative research and common regulatory structures, although national reimbursement and service capacity still influence adoption. G7 countries generally possess advanced clinical, manufacturing, and research ecosystems, while facing workforce, cost, and supply-continuity challenges. GCC states are strengthening specialist healthcare and may use centralized centers to support complex therapies. NATO members have varied national systems but can benefit from shared standards for emergency preparedness, supply resilience, and specialist training.

Country Insights: Capability, Policy, and Access Vary Widely

Australia combines strong research capacity with geographic access challenges and a need for dependable isotope distribution. Brazil is building specialized nuclear medicine services, although regional disparities and logistics remain important considerations. Canada has advanced clinical expertise, with large distances and supply coordination affecting access. China is expanding domestic research, manufacturing, and clinical infrastructure under a substantial national healthcare system. France, Germany, Italy, and Spain have established European nuclear medicine capabilities, but implementation is influenced by national assessment, reimbursement, and workforce arrangements. India has leading specialist centers alongside pronounced differences in access between major cities and other areas. Japan and South Korea possess mature technical and clinical capabilities, supported by advanced healthcare systems. Mexico is developing capacity through specialist institutions and international cooperation. Russia maintains nuclear science and medical capabilities, with access shaped by domestic infrastructure and supply conditions. The United Kingdom has strong academic and clinical expertise, while commissioning, isotope availability, and service capacity influence treatment access. The United States has extensive research, manufacturing, and specialist infrastructure, with coverage, site readiness, and distribution requirements affecting practical availability.

Action Priorities for Leaders: Build Reliable, Evidence-Based Care Pathways

Industry leaders should prioritize end-to-end resilience: secure diversified isotope supply, qualify backup logistics, and expand validated production and quality-control capacity. Clinical programs should establish multidisciplinary governance, standardized patient-selection criteria, dosimetry workflows, radiation-safety procedures, and structured outcome registries. Partnerships with hospitals, regulators, academic centers, and logistics providers can accelerate evidence generation while preserving compliance. Organizations should also invest in workforce development for radiopharmacy, nuclear medicine, oncology, medical physics, and nursing. AI initiatives should begin with clearly defined clinical use cases, prospective validation, bias monitoring, and auditable decision support. Finally, access strategies should address reimbursement evidence, regional referral models, patient communication, and equitable availability rather than focusing only on technical product performance.

Research Methodology: Evidence-Based Market Assessment

This executive summary is based on the defined scope of nuclear radiation therapeutic drugs and a structured assessment of clinical, technological, regulatory, operational, and geographic factors. The analysis organizes evidence around treatment mechanisms, theranostic development, isotope production and logistics, healthcare infrastructure, workforce requirements, artificial-intelligence applications, and policy conditions. Regional, group, and country observations are presented qualitatively and avoid unsupported estimates, market shares, forecasts, or company-specific claims. Interpretation should be updated as clinical guidelines, regulatory decisions, isotope supply conditions, and peer-reviewed evidence evolve.

Conclusion: Sustainable Adoption Depends on Integrated Capability

Nuclear radiation therapeutic drugs are advancing through more precise targeting, theranostic decision-making, improved dosimetry, and closer integration with oncology care. The principal adoption challenge is not technology alone; it is the coordination of evidence, isotope supply, manufacturing quality, specialist services, regulation, reimbursement, and patient follow-up. Regions and countries with integrated infrastructure and resilient supply pathways will be better positioned to translate innovation into routine care. Leaders should therefore pursue disciplined clinical validation, operational preparedness, responsible AI adoption, and access-oriented partnerships.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Nuclear Radiation Therapeutic Drugs Market, by Product Type
7.1. Introduction
7.2. Radioconjugate
7.2.1. Antibody Conjugate
7.2.2. Small Molecule Conjugate
7.3. Radioimmunotherapy
7.3.1. Bifunctional Antibody
7.3.2. Pretargeted Therapy
7.4. Radiopharmaceutical
7.4.1. Peptide Receptor Ligand Therapy
7.4.2. Psma Ligand Therapy
8. Nuclear Radiation Therapeutic Drugs Market, by Therapeutic Application
8.1. Introduction
8.2. Bone Metastases
8.3. Neuroendocrine Tumors
8.4. Prostate Cancer
8.5. Thyroid Cancer
9. Nuclear Radiation Therapeutic Drugs Market, by Radionuclide Type
9.1. Introduction
9.2. Alpha Emitter
9.3. Beta Emitter
10. Nuclear Radiation Therapeutic Drugs Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Nuclear Radiation Therapeutic Drugs Market, by End User
11.1. Introduction
11.2. Cancer Treatment Centers
11.3. Hospitals
11.4. Research Institutes
12. Nuclear Radiation Therapeutic Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Third Party Logistics
13. Nuclear Radiation Therapeutic Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Nuclear Radiation Therapeutic Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Nuclear Radiation Therapeutic Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Bayer AG
17.2. Cardinal Health, Inc.
17.3. Curium Pharma
17.4. Eckert & Ziegler Strahlen- und Medizintechnik AG
17.5. GE HealthCare Technologies Inc.
17.6. International Isotopes Inc.
17.7. Jubilant Life Sciences Limited
17.8. Lantheus Holdings, Inc.
17.9. Novartis AG
17.10. Siemens Healthineers AG
17.11. Telix Pharmaceuticals Limited
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Nuclear Radiation Therapeutic Drugs Market, Years Considered for the Study
FIGURE 2. Global Nuclear Radiation Therapeutic Drugs Market, Research Design
FIGURE 3. Global Nuclear Radiation Therapeutic Drugs Market, Research Framework
FIGURE 4. Global Nuclear Radiation Therapeutic Drugs Market, Data Triangulation
FIGURE 5. Global Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 9. Global Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2025 vs 2032 (%)
FIGURE 11. Global Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 13. Global Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Nuclear Radiation Therapeutic Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Nuclear Radiation Therapeutic Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Nuclear Radiation Therapeutic Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Nuclear Radiation Therapeutic Drugs Market Segmentation & Coverage
TABLE 2. Global Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Radioconjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Radioconjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Radioconjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Antibody Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Antibody Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Antibody Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Small Molecule Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Small Molecule Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Small Molecule Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Radioimmunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Radioimmunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Radioimmunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Bifunctional Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Bifunctional Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Bifunctional Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Pretargeted Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Pretargeted Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Pretargeted Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Radiopharmaceutical Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Radiopharmaceutical Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Radiopharmaceutical Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Peptide Receptor Ligand Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Peptide Receptor Ligand Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Peptide Receptor Ligand Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Psma Ligand Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Psma Ligand Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Psma Ligand Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 32. Global Bone Metastases Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Bone Metastases Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Bone Metastases Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Neuroendocrine Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Neuroendocrine Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Neuroendocrine Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Thyroid Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Thyroid Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Thyroid Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 45. Global Alpha Emitter Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Alpha Emitter Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Alpha Emitter Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Beta Emitter Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Beta Emitter Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Beta Emitter Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 52. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. Global Cancer Treatment Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Cancer Treatment Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Cancer Treatment Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 69. Global Direct Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Direct Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Direct Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Third Party Logistics Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Third Party Logistics Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Third Party Logistics Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. North America Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. North America Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 88. North America Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 89. North America Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 90. North America Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 91. North America Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 92. North America Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 93. North America Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 94. North America Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. North America Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 98. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 99. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 100. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 101. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 102. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 103. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 104. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Latin America Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 108. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 109. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 110. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 111. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 112. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 113. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 114. Europe Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. Europe Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 118. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 119. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 120. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 121. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 122. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 123. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 124. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Middle East Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 128. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 129. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 130. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 131. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 132. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 133. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 134. Africa Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Africa Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Global Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 139. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 140. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 141. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 142. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 143. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 144. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 145. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. ASEAN Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 150. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 151. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 152. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 153. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 154. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 155. GCC Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. GCC Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 160. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 161. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 162. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 163. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 164. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 165. European Union Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. European Union Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 169. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 170. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 171. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 172. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 173. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 174. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 175. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. BRICS Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 179. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 180. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 181. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 182. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 183. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 184. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 185. G7 Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 186. G7 Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 189. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 190. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 191. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 192. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 193. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 194. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 195. NATO Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. NATO Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Global Nuclear Radiation Therapeutic Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 198. United States Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 199. United States Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 200. United States Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 201. United States Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 202. United States Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 203. United States Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 204. United States Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 205. United States Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 206. United States Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. United States Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. Canada Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 209. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 210. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 211. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 212. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 213. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 214. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 215. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 216. Canada Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Canada Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. Mexico Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 219. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 220. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 221. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 222. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 223. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 224. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 225. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 226. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Mexico Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. Brazil Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 229. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 230. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 231. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 232. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 233. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 234. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 235. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 236. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Brazil Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 239. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 240. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 241. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 242. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 243. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 244. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 245. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 246. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 247. United Kingdom Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. Germany Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 249. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 250. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 251. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 252. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 253. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 254. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 255. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 256. Germany Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Germany Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. France Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 259. France Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 260. France Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 261. France Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 262. France Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 263. France Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 264. France Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 265. France Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 266. France Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. France Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Russia Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 269. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 270. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 271. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 272. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 273. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 274. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 275. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 276. Russia Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. Russia Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 278. Italy Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 279. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 280. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 281. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 282. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 283. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 284. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 285. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 286. Italy Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. Italy Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. Spain Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 289. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 290. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 291. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 292. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 293. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 294. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 295. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 296. Spain Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 297. Spain Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 298. China Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 299. China Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 300. China Nuclear Radiation Therapeutic Drugs Market Size, by Radioconjugate, 2017-2032 (USD Million)
TABLE 301. China Nuclear Radiation Therapeutic Drugs Market Size, by Radioimmunotherapy, 2017-2032 (USD Million)
TABLE 302. China Nuclear Radiation Therapeutic Drugs Market Size, by Radiopharmaceutical, 2017-2032 (USD Million)
TABLE 303. China Nuclear Radiation Therapeutic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 304. China Nuclear Radiation Therapeutic Drugs Market Size, by Radionuclide Type, 2017-2032 (USD Million)
TABLE 305. China Nuclear Radiation Therapeutic Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 306. China Nuclear Radiation Therapeutic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 307. China Nuclear Radiation Therapeutic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 308. India Nuclear Radiation Therapeutic Drugs Market Size, 2017-2032 (USD Million)
TABLE 309. India Nuclear Radiation Therapeutic Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 310. India Nuclear Radiation Therapeutic Drugs Market Siz

Companies Mentioned

  • Bayer AG
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler Strahlen‑ und Medizintechnik AG
  • GE HealthCare Technologies Inc.
  • International Isotopes Inc.
  • Jubilant Life Sciences Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032 - Product Image

Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Nuclear Radiation Contamination Detector Market - Global Forecast 2026-2032 - Product Image

Nuclear Radiation Contamination Detector Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Therapeutic Nuclear Drug Market Report 2026 - Product Image

Therapeutic Nuclear Drug Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Nuclear Protein in Testis Midline Carcinoma Treatment Market Report 2026 - Product Image

Nuclear Protein in Testis Midline Carcinoma Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Nuclear Pharmacy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Nuclear Pharmacy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.